Harrow (NASDAQ:HROW) Stock Price Down 4.6% – Time to Sell?

Harrow, Inc. (NASDAQ:HROW) was down 4.6% during mid-day trading on Wednesday . The company traded as low as $25.17 and last traded at $25.74. Approximately 93,816 shares traded hands during trading, a decline of 81% from the average daily volume of 501,370 shares. The stock had previously closed at $26.98.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on HROW shares. B. Riley decreased their target price on shares of Harrow from $73.00 to $69.00 and set a “buy” rating for the company in a research report on Wednesday, December 4th. HC Wainwright restated a “buy” rating and set a $57.00 target price on shares of Harrow in a research report on Tuesday.

Harrow Stock Performance

The company has a current ratio of 1.55, a quick ratio of 1.44 and a debt-to-equity ratio of 3.23. The firm’s 50-day moving average is $30.01 and its two-hundred day moving average is $38.63. The stock has a market cap of $940.56 million, a price-to-earnings ratio of -28.01 and a beta of 0.69.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of HROW. Principal Financial Group Inc. purchased a new stake in Harrow during the 3rd quarter valued at about $329,000. Oppenheimer & Co. Inc. purchased a new stake in Harrow during the 3rd quarter valued at about $1,267,000. Quest Partners LLC purchased a new stake in Harrow during the 3rd quarter valued at about $29,000. First Turn Management LLC purchased a new stake in Harrow during the 3rd quarter valued at about $14,683,000. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new stake in Harrow during the 3rd quarter valued at about $5,864,000. Institutional investors and hedge funds own 72.76% of the company’s stock.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.